Endocrine 2 Flashcards
DM1
Autoimmune Pancreatic beta cells destroyed (Islets of Langerhans) No insulin produced Glucose ^^^
DM2
Excess adipose tissue
Relative insulin deficiency
Glucose ^
Prediabetes
Not meeting DM2 criteria
Likely to develop DM2 in next few years
Require lifestyle interventions
Fasting glucose 6.1-6.9
HbA1c 42-47
DM2 risk factors
Age ^
Family history
Non-white
Sedentary lifestyle
Obesity
Stress
GDM
PCOS
HTN
Dyslipidaemia
CVD
DM clinical features
Polydipsia
Polyuria
Weight loss
Fatigue
Visual disturbances
Abdo pain
N/V
Recurrent infections
- Candidal
- Skin
- UTI
Polydipsia/polyuria pathophysiology
Glycosuria
Water follows by osmosis
= Dehydration
DM investigations
Random plasma glucose > 11
Fasting plasma glucose > 6.9
OGTT - 75g glucose - Wait 2 hours - Positive > 11
HbA1c > 48
Urine dip - Ketones +++
DM1 management
Insulin
- SC pump
- 0.2-0.4 units/kg/day
- BM self-monitoring
- Pre-meal insulin correction dose
DM2 management - Lifestyle
Lifestyle changes (HbA1c 48-53)
- Weight loss 5-10%
- Physical activity
- Reduce alcohol intake - Risk of hypo
- Smoking cessation
Diet - Reduce sugar consumption
- High fibre
- Low GI foods
- Low-fat dairy produts
- Reduced saturated fats and TFAs
DM sick day rules
Increase frequency of BM monitoring Increase fluid intake - 3L / 24 hours Maintain carbohydrate intake - Sugary drinks if necessary Access to a mobile phone Continue medication - Except metformin
DM indications for admission
Inability to tolerate oral fluids Persistent diarrhoea Significant ketosis - Despite additional insulin BM > 20 - Despite additional insulin Lack of support at home
DM2 management
- HbA1c 48-53 - Diet and exercise
- Metformin
- If HbA1c > 58 add…
- Gliptin
- Sulfonylurea
- Pioglitazone
- SGLT-2 inhibitor - Gliflozin - If HbA1c > 58 - Add another
- If HbA1c > 58 and BMI > 35
- Add GLP-1 mimetic
DM drugs MoA
Metformin - CI if eGFR < 30
- Increases insulin sensitivity
- Decreases hepatic gluconeogenesis
Sulfonylurea - Gliclazide
- Risk of hypoglycaemia
- Stimulates pancreatic B cells to produce insulin
Pioglitazone
- Promote adipogenesis and FFA uptake
- Weight gain
Gliptins
- Increases incretin
- Inhibits glucagon secretion
- Risk of pancreatitis
SGLT-2 inhibitors - Inhibits renal reabsorption of glucose
DM complications
Microvascular
- Neuropathy
- Retinopathy
- Neuropathy
Macrovascular
- CVD
- CHF
- Stroke
Infection
DKA
Non-ketotic hyperosmolar state
DKA pathophysiology
Insulin deficiency + Glucagon ^
Triglycerides and AAs metabolised for energy
Increased serum glycerol and FFA
Glucagon converts FFA to ketones
Hyperglycaemia causes osmotic diuresis
Marked urinary loss of water and electrolytes
DKA clinical features
N/V
Abdo pain
Altered consciousness
Dehydration
Hyperventilation - Kussmaul breathing
Ketone breath - Pear drops
Sx of DM
DKA investigations
VBG
- Hyperkalaemia
- Hypokalaemia = Severe DKA
- Metabolic acidosis
- Serum osmolality ^^^
pH < 7.3
Serum ketones > 3
BM > 11
Bicarb < 15
DKA management
Fluid replacement
- 500ml bolus over 10-15 minutes
- 1L over 1 hour
Correct hypokalaemia - SandoK
Insulin - FR infusion
When glucose < 14 - Give 10% Dextrose
Safe rate of glucose reduction - 4-6 mmol/hr
DKA complications
Arrhythmias - Hypo/hyperkalaemia
VTE
ARDS
Gastric stasis
AKI
Cerebral oedema
Hyperosmolar hyperglycaemic state pathophysiology
Hyperglycaemia Osmotic diuresis - Electrolyte abnormalities - Severe dehydration - Raised serum osmolality - Hyperviscosity
Typically elderly DM2 patients
Develops over many days
Hyperosmolar hyperglycaemic state clinical features
Dehydration
Hypotension
Tachycardia
Fatigue
Lethargy
Weakness
Altered consciousness
N/V
Headaches
Papilloedema